SG Americas Securities LLC Cuts Holdings in Hologic, Inc. $HOLX

SG Americas Securities LLC lessened its holdings in Hologic, Inc. (NASDAQ:HOLX) by 50.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,731 shares of the medical equipment provider’s stock after selling 4,878 shares during the period. SG Americas Securities LLC’s holdings in Hologic were worth $308,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in HOLX. Chung Wu Investment Group LLC acquired a new position in Hologic in the 2nd quarter valued at $26,000. Caitong International Asset Management Co. Ltd raised its position in Hologic by 193.6% in the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 273 shares during the period. Zions Bancorporation National Association UT purchased a new stake in shares of Hologic in the 1st quarter valued at $34,000. Cromwell Holdings LLC lifted its position in shares of Hologic by 307.0% during the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock worth $38,000 after purchasing an additional 436 shares in the last quarter. Finally, Avalon Trust Co acquired a new stake in Hologic during the 2nd quarter worth approximately $98,000. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently weighed in on HOLX shares. BNP Paribas Exane cut Hologic from an “outperform” rating to a “neutral” rating and set a $79.00 target price for the company. in a research note on Friday, November 21st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hologic in a research report on Friday, October 31st. Wall Street Zen cut Hologic from a “buy” rating to a “hold” rating in a research note on Wednesday, October 1st. Evercore ISI set a $78.00 target price on shares of Hologic and gave the company an “outperform” rating in a report on Tuesday, October 7th. Finally, BNP Paribas cut shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price target for the company. in a research note on Friday, November 21st. Five analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company. According to data from MarketBeat, Hologic has a consensus rating of “Hold” and an average target price of $79.67.

Hologic Price Performance

Shares of NASDAQ HOLX opened at $74.98 on Friday. The stock has a fifty day moving average price of $71.48 and a 200 day moving average price of $67.02. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $80.31. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The company has a market cap of $16.71 billion, a PE ratio of 31.11, a P/E/G ratio of 2.54 and a beta of 0.65.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.03 billion. During the same quarter in the prior year, the firm earned $1.01 EPS. Hologic’s quarterly revenue was up 6.2% on a year-over-year basis. Sell-side analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Transactions at Hologic

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the sale, the chief executive officer owned 1,234,624 shares of the company’s stock, valued at approximately $82,682,769.28. The trade was a 10.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christiana Stamoulis sold 7,402 shares of the business’s stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $73.07, for a total value of $540,864.14. Following the transaction, the director owned 47,336 shares in the company, valued at $3,458,841.52. The trade was a 13.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 1.88% of the stock is owned by company insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.